Quarterly report pursuant to Section 13 or 15(d)

Business Combinations

v2.4.0.8
Business Combinations
9 Months Ended
Jun. 28, 2014
Business Combinations [Abstract]  
Business Combinations
2. Business Combinations

Four Star Microbial Products

In December 2012, the Company acquired the remaining majority interest in FourStar Microbial Products, LLC (Four Star Microbial) for approximately $4.8 million in cash and approximately $4.2 million of contingent future performance-based payments. The purchase price exceeded the estimated fair value of the tangible and intangible assets acquired by $3.2 million, which was recorded as goodwill. The operating results of FourStar Microbial had no material impact on the consolidated financial statements.

The following table summarizes the preliminary recording of the fair values of the assets acquired and liabilities assumed as of the acquisition date and subsequent adjustments:

 

(In thousands)

  Amounts
Previously
Recognized as of
Acquisition Date(1)
    Measurement
Period
Adjustments
    Amounts
Recognized as of
Acquisition Date
(as Adjusted)
 

Current assets, net of cash and cash equivalents acquired

  $ 220      $ 0      $ 220   

Fixed assets

    40        0        40   

Goodwill

    0        3,243        3,243   

Intangible assets

    1,144        5,958        7,102   

Other long-term assets

    5,406        (5,406     0   

Current liabilities

    (13     0        (13

Other long-term liabilities

    0        (4,165     (4,165
 

 

 

   

 

 

   

 

 

 
    6,797        (370 )(2)      6,427   

Assets of aquiree recorded prior to purchase of majority interest

    (1,962     370        (1,592
 

 

 

   

 

 

   

 

 

 

Net assets acquired, less cash and cash equivalents

  $ 4,835      $ 0      $ 4,835   
 

 

 

   

 

 

   

 

 

 

 

(1) As previously reported in our Form 10-Q for the period ended December 29, 2012.
(2) The Company recognized a loss of approximately $370 on its prior ownership interest in the acquiree.

 

During fiscal 2013, the fair value measurements of assets acquired and liabilities assumed of FourStar Microbial as of the acquisition date were refined. This refinement did not have a significant impact on the Company’s condensed consolidated statements of operations, balance sheets or cash flows in any period and, therefore, the Company has not retrospectively adjusted its financial statements. These fair value assessments were finalized and reflected in the Company’s Form 10-K for the year ended September 28, 2013. Financial results for FourStar Microbial have been included in the results of operations within the Pet segment since the date of acquisition.

Envincio

On April 1, 2014, the Company purchased certain assets of Envincio LLC, including brands, EPA registrations, inventory and trade receivables, for approximately $20 million. The purchase price exceeded the fair value of the net tangible assets acquired by approximately $14 million, which is included in deferred taxes and other assets in our condensed consolidated balance sheets as of June 28, 2014, as the Company has not yet finalized the allocation of the purchase price to the fair value of the intangible assets acquired. The operating results of this acquisition did not have a material impact on the Company’s consolidated financial statements. This acquisition is expected to enable the Company to be a key supplier and product innovator in the growing natural insecticides product market, often characterized as EPA-exempt products, and expand its offerings in traditional pesticides.